STEPHEN MATTHEWS: Open Payments
NPI 1154011526 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,450 in 46 payments from 17 companies in 2025. Trend: 2023 $125 · 2024 $264 · 2025 $1,450
Food & beverage: $1,450
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $318 |
| Axsome Therapeutics, Inc. | 3 | $253 |
| ACADIA Pharmaceuticals Inc | 8 | $167 |
| Eisai Inc. | 4 | $140 |
| SK Life Science, Inc. | 3 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| TG Therapeutics, Inc. | 2 | $70 |
| PFIZER INC. | 1 | $62 |
| Genentech USA, Inc. | 2 | $56 |
| UCB, Inc. | 1 | $32 |
Products named: Symbravo, QULIPTA, NUPLAZID, Leqembi, AUSTEDO XR, XCOPRI, BRIUMVI, NURTEC ODT.
Industry payments across NE — which companies pay providers there.
